OBIO – orchestra biomed holdings, inc. - ordinary shares (US:NASDAQ)
Stock Stats
News
Orchestra BioMed Announces AVIM Therapy Global Intellectual Property Estate Reaches 110 Issued Patents
Orchestra BioMed to Host In-Person R&D Day in New York on AVIM Therapy Program in Hypertensive Pacemaker Patients on June 11, 2024
Orchestra BioMed Holdings, Inc. (NASDAQ: OBIO) had its "buy" rating re-affirmed by analysts at Chardan Capital. They now have a $20.00 price target on the stock.
Orchestra BioMed Reports Full Year 2023 Financial Results and Provides Fourth Quarter Business Update
Orchestra BioMed Announces Appointment of Medical Device Industry Expert David Pacitti to Board of Directors
Top News Gainers
Top News Decliners
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.